What is GlycoSeLect?
GlycoSeLect Ltd. is at the forefront of developing and producing Recombinant Prokaryotic Lectins (RPLs), advanced glycoselective bioaffinity proteins. These innovative proteins are engineered for the efficient detection, analysis, and isolation of glycosylated biomolecules, offering a substantial upgrade over conventional methods in both analytical and purification processes. The company's capability for scalable production supports applications from research to industrial scale, serving the dynamic needs of the Life Science Industries. GlycoSeLect's mission is to equip the biopharmaceutical sector and related fields with superior glycoselective tools to accelerate research and development initiatives.
How much funding has GlycoSeLect raised?
GlycoSeLect has raised a total of $528K across 1 funding round:
Angel/Seed
$528K
Angel/Seed (2017): $528K, investors not publicly disclosed
What's next for GlycoSeLect?
The recent major strategic investment signals a pivotal moment for GlycoSeLect, likely enabling the company to scale its operations, expand its product development pipeline, and broaden its market reach within the biopharmaceutical and life sciences sectors. This capital infusion is expected to fuel further innovation in RPL technology and solidify its position as a key provider of advanced glycoselective tools for complex biomolecule analysis and purification.
See full GlycoSeLect company page
